I generally avoid writing about subjects that require highly specialized expertise. The 340B Drug Pricing Program certainly falls into that category. It is complex, highly technical, and the subject of ongoing debate among hospitals, pharmaceutical companies, policymakers, and patient advocates.

So why write about it?

Because I suspect most people, including many patients who benefit from it indirectly, have never heard of the 340B Program or understand why it matters. While the policy debates often dominate the headlines, the real story is how this program quietly helps hospitals and healthcare providers preserve services that entire communities rely upon.

This article isn’t intended to weigh in on every argument surrounding the program. Instead, it seeks to answer a much simpler question:

Why should the average patient care about the 340B Program?

The 340B Drug Pricing Program was created by Congress in 1992 as part of the Veterans Health Care Act. Its purpose was straightforward: help hospitals, community health centers, and other healthcare providers that serve large numbers of low-income, uninsured, and vulnerable patients stretch limited financial resources while expanding access to care.

According to the Health Resources and Services Administration (HRSA), which oversees the program, “The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”

The program works through a simple exchange. Pharmaceutical manufacturers that want their outpatient drugs covered under Medicaid and certain Medicare programs agree to provide significant discounts on those medications to qualifying healthcare providers. Those discounts, often ranging from 20 to 50 percent, create financial savings that hospitals and clinics can reinvest into patient care and community services.

For many safety-net providers, the program has been enormously valuable. It has allowed hospitals to expand services, improve access to care, and continue caring for patients regardless of their ability to pay.

Ironically, that success has also made the program increasingly controversial.

Over the past decade, the 340B Program has grown dramatically. Discounted drug purchases increased from approximately $30 billion in 2015 to nearly $100 billion in 2025, making it the nation’s second-largest federal drug pricing program. That growth has been fueled by rising specialty drug costs, pharmaceutical price inflation, and an increase in the number of eligible hospitals and contract pharmacies.

Not surprisingly, that rapid expansion has intensified opposition from pharmaceutical manufacturers, many of whom argue that the program has grown beyond its original intent. Hospitals, on the other hand, maintain that the program has become even more essential as they face rising labor costs, increasing numbers of uninsured and underinsured patients, and growing financial pressures.

But what does all of this mean for someone with good health insurance?

Surprisingly, quite a bit.

Most privately insured patients never receive a direct discount on the prescriptions they fill because of the 340B Program. Instead, they benefit from something much broader.

The savings generated through 340B allow hospitals to maintain services that often lose money but are essential to the community. These include trauma centers, behavioral health programs, cancer services, mobile clinics, neonatal intensive care units, substance use disorder treatment programs, and other services that hospitals simply cannot abandon because their communities depend on them.

Hospitals also use these resources to help subsidize care for uninsured and underinsured patients, strengthen community outreach programs, and invest in services that improve health outcomes beyond the walls of the hospital.

In many communities, particularly rural and underserved areas, 340B funding also helps hospitals remain financially viable. Without those resources, some hospitals would be forced to reduce services or, in extreme cases, close altogether.

Ultimately, these investments benefit everyone, not just the uninsured. By helping hospitals absorb some of the financial pressures associated with caring for vulnerable populations, the 340B Program strengthens the entire healthcare delivery system. It also influences what hospitals must seek from commercial insurers during contract negotiations, helping offset the costs of services that otherwise would have no sustainable source of funding.

The debate over the future of the 340B Program will undoubtedly continue. Like many complex public policy issues, there are legitimate questions about oversight, accountability, and modernization. But amid those discussions, it is important not to lose sight of its original purpose. The program was created to strengthen the healthcare safety net, and for millions of Americans it continues to do exactly that.

Whether you have private insurance, Medicare, Medicaid, or no insurance at all, chances are your local hospital provides services that are supported, directly or indirectly, by the 340B Program. It may never reduce the price of the prescription you pick up at the pharmacy, but it helps ensure that when you or someone you love needs emergency care, trauma services, cancer treatment, behavioral health care, or other essential healthcare services, those resources are available close to home.

Sometimes the most valuable healthcare programs are the ones patients never realize are quietly working on their behalf.

The 340B Program is not simply about discounted drugs. It is about preserving access to healthcare for entire communities, often long before any of us become patients.